Dr. Scott Carroll reports

CANNARA ESTABLISHES AUTOMATIC SHARE PURCHASE PLAN

In connection with Cannara Biotech Inc.'s previously announced normal course issuer bid (NCIB) to purchase up to 1,975,642 of its common shares during the 12-month period commencing Aug. 4, 2026, and ending Aug. 3, 2027, it has entered into an automatic share purchase plan (ASPP) with Integral Wealth Securities Ltd. acting as its designated broker. The ASPP is intended to allow for the purchase of shares under the NCIB during predetermined circumstances Cannara would ordinarily not be permitted to purchase shares due to regulatory restrictions and customary blackout periods.

The company has authorized Integral to make purchases under the NCIB in accordance with the terms of the ASPP. Such purchases will be determined by Integral at its sole discretion based on certain parameters as to price and number of shares set by Cannara in accordance with the rules of the Toronto Stock Exchange (TSX), applicable securities laws and the terms of the ASPP.

Under the terms of the NCIB, the company may purchase up to a daily maximum of 10,469 shares (being equal to 25 per cent of the average daily trading volume of 41,879 shares on the TSX). As Cannara's shares only commenced trading on the TSX on March 2, 2026, following the company's graduation from the TSX Venture Exchange, the average daily trading volume has been calculated using the period from March 2, 2026, to June 30, 2026, rather than the six completed calendar months preceding the TSX's acceptance of the notice of the NCIB.

The ASPP constitutes an automatic plan for the purposes of applicable securities laws and has been precleared by the TSX. The ASPP will commence immediately and terminate when the NCIB expires, unless terminated earlier in accordance with the terms of the ASPP. The ASPP will terminate on the earliest of the date on which: (i) the purchase limit under the NCIB has been reached; (ii) the NCIB expires; and (iii) the ASPP otherwise terminates in accordance with its terms.

Outside of predetermined blackout periods, shares may be purchased under the NCIB based on management's discretion, in compliance with TSX rules and applicable securities laws. All purchases made under the ASPP will be included in computing the number of shares purchased under the NCIB. Any shares that are purchased under the NCIB will be cancelled.

About Cannara Biotech Inc.

Cannara Biotech is a vertically integrated producer of affordable premium-grade cannabis and cannabis-derivative products. Cannara owns two mega facilities based in Quebec spanning over 1.6 million square foot, providing the company with 100,000 kilograms of potential annualized cultivation output. Leveraging Quebec's favourable energy costs, Cannara maintains an efficient, low-cost production model.

We seek Safe Harbor.